Description
Anti-ERBB2 Antibody, Highly Galactosylated (BioBet-GA-218ZP) is a human IgG1, κ antibody against ERBB2 which contains with a high level of galactosylation.
Antibody Indication
Breast cancers overexpressing ERBB2, metastatic
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ERBB2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Erb-B2 Receptor Tyrosine Kinase 2
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
Alternative Names
Trastuzumab; Herclon, trastuzumab; 180288-69-1; Herclon; DB00072ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); NGL, v erb b2 avian erythroblastic leukemia viral oncogene homolog 2
Cellular Localization
Nucleus, Plasma membrane, Endosome
Involvement in Disease
Its related pathways are Association Between Physico-Chemical Features and Toxicity Associated Pathways and RET signaling.
Related Pathways
1.Protein tyrosine kinases are part of several cell surface receptor complexes, but obviously require a co-receptor to which a ligand binds. An essential component of the neurotonin receptor complex, although neurotonin does not interact with it alone. GP30 is a potential ligand for this receptor. Regulate the growth and stability of peripheral microtubules (MTs). After ERBB2 is activated, the memo1-rhoa-991 signaling pathway triggers the phosphorylation of GSK3B on the cell membrane, thereby inhibiting GSK3B. This prevents the phosphorylation of APC and CLASP2, allowing them to bind to the cell membrane. In turn, membrane-bound APC allows MACF1 to localize to the cell membrane, which is necessary for microtubule capture and stabilization. 2.Participate in transcriptional regulation in the nucleus. It is associated with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Participate in CDKN1A transcriptional activation; functions include STAT3 and SRC. Participate in the transcription of rRNA genes through RNA Pol I, and promote protein synthesis and cell growth.
Function
Cancer antibody; Controls and Markers antibody; Signaling Transduction antibody; Circulating Tumor Cells BioMarker antibody
Field of research
Autophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172).
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-GA-218ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human ErbB2. Trastuzumab (INN; trade names Herclon, trastuzumab) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell (molecules called EGFs) to inside the cell, and turn genes on and off. The HER proteins stimulate cell proliferation. In some cancers, notably certain types of breast cancer, HER2 is over-expressed, and causes cancer cells to reproduce uncontrollably.
Antibody Indication
Breast cancers overexpressing ERBB2, metastatic